Navigation Links
Anthera Announces First Quarter 2013 Financial Report and Conference Call
Date:5/3/2013

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on May 20th, 2013.

Conference Call Access:
Date:   Monday, May 20th, 2013
Time:   5:00 pm Eastern Time

Domestic Dial-in:        (877)312-8807
International Dial-in:   (253)237-1190
Conference ID:           64577060

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406.  The conference ID for the replay is 64577060. The audio replay will be available until May 27th, 2013. 

About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
2. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
3. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
4. Anthera to Report Second Quarter 2012 Financial Results
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... , Dec. 11, 2014 Research and Markets ... addition of the "Glucose Sensors: the Next ... http://photos.prnewswire.com/prnh/20130307/600769 The ... designs is giving hope for a better future ... monitors that can measure glucose levels accurately and ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. 12, ... announced the presentation of data at the San Antonio ... study evaluating epoetin alfa plus best supportive care (BSC) ... with metastatic breast cancer receiving standard chemotherapy. This non-inferiority ... to rule out a 15 percent or greater increase ...
(Date:12/12/2014)... Graphite Metallizing Corporation, the manufacturer of ... process equipment, has appointed Kirk Staller as Sales Engineering ... Staller holds a B.S. degree from Purdue University and ... place, much of it with a manufacturer of centrifugal ... office. , “We are pleased to have ...
(Date:12/12/2014)... 2014 Electronic Data Interchange (EDI) ... management and supply chain management to depend from ... The benefits associated with the use of EDI ... transactions has helped improve the acceptance of this ... market data tables and 107 figures spread through ...
Breaking Biology Technology:Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... Ill., July 29 The Board of,Directors of Baxter ... dividend of $0.2175 per share of Baxter common stock., ... rate, which was,increased earlier this year by 30 percent. ... shareholders of record as of September 10,2008., Baxter ...
... an Antipsychotic Agent with Less Potential for ... Gain and Metabolic Risks, SAN DIEGO, July 29 ... that the United States Patent and,Trademark Office (USPTO) issued ... provide broad coverage for a pharmaceutical,composition of zonisamide in ...
... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced ... in a,single-center, Phase 1 trial of recombinant, ... its Wnt Therapeutics Program. This,double-blind, placebo-controlled, single-ascending ... and pharmacokinetics of a single,intravenous (IV) administration ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... toxins or nefarious germs, smaller and faster is better. ... especially when measurements by different instruments must give the ... standarda culmination of years of research at the National ... from handheld chemical detectors can be compared, apples-to-apples. ...
... of the most species-rich ant genera, latest research has stripped ... species- Paratrechina longicornis . This particular ant is one ... tropical and subtropical location on the planet due to accidental ... invasive ant species. A recent review of the genus in ...
... news release is available in German . ... on a course of treatment, tests can be carried out ... is likely to be effective. But the time-consuming and expensive ... Collaborating with DITABIS Digital Biomedical Imaging Systems AG and scientists ...
Cached Biology News:New spectrometry standard for handheld chemical detectors aids first responders 2The most widespread ant and its new relative: A revision of the genus Paratrechina 2A cost-effective way toward personalized cancer drugs 2A cost-effective way toward personalized cancer drugs 3